Navigation Links
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Date:6/6/2013

tential bioequivalence (BE) to Abraxane® to get Cynviloq™ to the market quickly and at minimal cost using the FDA 505(b)(2) BE application pathway that allows companies to obtain FDA approval of new drug applications (NDAs) for reformulations of drugs with the same active ingredient.

"Sorrento is unique in its ability to potentially have an approved oncology product within the next few years using an abbreviated 505(b)(2) BE pathway at a fraction of the cost of what is spent by traditional drug development companies," noted Frost & Sullivan Industry Analyst Justin Collishaw . "Our independent analysis confirms that other competitors lack similar near-term approvable therapies, which may be able to generate revenues in the next three to four years."

Sorrento, through its IGDRASOL acquisition, also secured EU distribution rights, which give Sorrento the flexibility to form alliances with multinational companies seeking late-stage drug products to fill in gaps in their pipeline. In addition, Sorrento is moving forward in the field of true personalized medicine with the development of Therapeutic Drug Monitoring (TDM), which will complement and expand the Cynviloq™ franchise in the market.

Sorrento's next strength lies in its outstanding management team that boasts an impressive track record of long-term vision and timely execution. Such an industry-leading management team will help Sorrento's valuable products reach their full potential.

"Partnership with large pharma could accelerate Sorrento's development program and broaden its portfolio into inflammation and infectious diseases," noted Collishaw. "As a publicly traded company, Sorrento has the added advantage of access to the public investment market."

Sorrento is further consolidating its market position by targeting therapeutic areas with an unmet need. The company is selecting antibody candidates that have strong
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... PLYMOUTH MEETING, Pa. , Sept. 18, ... eClinical trial solutions, was recognized as the ... 2014 for its ePharmaONE cloud-based eClinical platform. ... portal and electronic trial master file (eTMF), ... informed-consent solution, and ePharmaSolutions, ReferralPlus+ patient screening ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   (NYSE: ... Simbionix RobotiX Mentor™ , a new robotic surgery skills ... first time at the ERUS exhibition in Amsterdam, ... #7). Robotic-assisted minimally invasive surgery represents a growing ... the needs for training for robotic surgery has increased, and ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:9/18/2014)... 2014 Memorial Cardiac and Vascular ... week by performing the first ever, adult heart transplant ... for Organ Sharing) approval to launch the adult heart ... two programs in South Florida. , The skilled ... Gongora, Medical Director of the Adult Heart Transplant ...
(Date:9/18/2014)... September 19, 2014 A jacket is ... A jacket typically has sleeves, and fastens in the ... generally lighter, tighter-fitting, and less insulating than a coat, ... serve as protective clothing. Today, Fecbek, a well-known clothing ... of trendy men’s jackets; all these items are offered ...
(Date:9/18/2014)... Sept. 18, 2014 (HealthDay News) -- Rising temperatures in ... to spread to shallow waters that are becoming warmer, ... coral reefs, ecologists report. A study of 40 ... shows northward movement by the invasive and poisonous lionfish, ... Administration (NOAA) and the University of North Carolina-Wilmington, who ...
(Date:9/18/2014)... Steven Reinberg HealthDay Reporter ... sign that the Ebola outbreak in West Africa is starting to ... more than 700 new cases of the deadly viral infection were ... of cases to more than 5,300, with roughly half of those ... reported. The number of deaths now tops 2,600. WHO has ...
(Date:9/18/2014)... 18, 2014 Limited spots remain at ... Only 100 spots are still available for Becker's ASC ... ASCs on October 23-25, 2014 at the Swissotel Chicago. ... Chief Information Officer Strategy Roundtable on November 4, 2014 ... remain for Becker's Hospital Review Chief Executive Officer Strategy ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2
... for Complimentary Services and Fund Raising Program In ... 15 Westside Medical Spa today,announced the launch of "Face ... preparing to embark on a new chapter in their lives.,Structured ... the,Day" has partnered with Jenesse Center Inc., in support of ...
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... of evidence-based medicines available for patients,living with less ... financial and business results for the third quarter ... Aspreva will host a conference call to discuss ...
... for Unwanted Babies, Prevents Abandonment, HARRISBURG, Pa., Oct. ... today reminded expectant,parents and parents of newborns that Pennsylvania,s ... infants, up to 28 days old, to,any hospital as ... Sharon, Mercer County, a newborn girl was found in ...
... issue of the Journal of General Internal Medicine, geriatrics researchers ... Center for Aging Research and the Regenstrief Institute, Inc. say ... adults, cannot meet the needs of the growing number of ... system approaches dementia. , We have a ...
... Comment on Role of Screening,Colonoscopy in Reducing ... Today,s news from the,CDC and American ... cancer,deaths in the United States includes heartening ... of the nation,s leading gastrointestinal,specialists are convening ...
... Obligations to Laurus Fully Repaid, LARGO, Fla., ... Board: DYHP.OB) ("Dynamic"), a leading distributor in,the sports ... it filed its Articles of Merger with the ... Nasdaq of its merger with GeoPharma, Inc.,(Nasdaq: ...
Cached Medicine News:Health News:Westside Medical Spa Launches 'Face the Day' to Aid Battered Women 2Health News:Aspreva to Announce 2007 Third Quarter Results on October 31st 2Health News:PA Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2Health News:Editorial says primary care system must change how it approaches dementia 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
... have been designed to optimize the accuracy ... our tip products is widely recognized by ... has been extended over the years and ... and special tips including filter tips, certified ...
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
The LH ELISA kit is used for the quantitative measurement of LH in human serum or plasma....
Medicine Products: